EA201400950A1 - Способы распространения комплемент-ингибирующих лекарственных средств среди пациентов, получающих ингибитор комплемента - Google Patents

Способы распространения комплемент-ингибирующих лекарственных средств среди пациентов, получающих ингибитор комплемента

Info

Publication number
EA201400950A1
EA201400950A1 EA201400950A EA201400950A EA201400950A1 EA 201400950 A1 EA201400950 A1 EA 201400950A1 EA 201400950 A EA201400950 A EA 201400950A EA 201400950 A EA201400950 A EA 201400950A EA 201400950 A1 EA201400950 A1 EA 201400950A1
Authority
EA
Eurasian Patent Office
Prior art keywords
complete
patients
methods
distributing
inhibitor
Prior art date
Application number
EA201400950A
Other languages
English (en)
Russian (ru)
Inventor
Леонард Белл
Original Assignee
Алексион Фармасьютикалс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Алексион Фармасьютикалс, Инк. filed Critical Алексион Фармасьютикалс, Инк.
Publication of EA201400950A1 publication Critical patent/EA201400950A1/ru

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H70/00—ICT specially adapted for the handling or processing of medical references
    • G16H70/40—ICT specially adapted for the handling or processing of medical references relating to drugs, e.g. their side effects or intended usage
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F04—POSITIVE - DISPLACEMENT MACHINES FOR LIQUIDS; PUMPS FOR LIQUIDS OR ELASTIC FLUIDS
    • F04C—ROTARY-PISTON, OR OSCILLATING-PISTON, POSITIVE-DISPLACEMENT MACHINES FOR LIQUIDS; ROTARY-PISTON, OR OSCILLATING-PISTON, POSITIVE-DISPLACEMENT PUMPS
    • F04C2270/00—Control; Monitoring or safety arrangements
    • F04C2270/04—Force
    • F04C2270/041—Controlled or regulated

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Medical Informatics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Primary Health Care (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EA201400950A 2012-03-16 2012-03-16 Способы распространения комплемент-ингибирующих лекарственных средств среди пациентов, получающих ингибитор комплемента EA201400950A1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2012/029499 WO2013137912A2 (en) 2012-03-16 2012-03-16 Methods of distributing complement-inhibiting drugs to patients receiving a complement inhibitor

Publications (1)

Publication Number Publication Date
EA201400950A1 true EA201400950A1 (ru) 2014-12-30

Family

ID=49161929

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201400950A EA201400950A1 (ru) 2012-03-16 2012-03-16 Способы распространения комплемент-ингибирующих лекарственных средств среди пациентов, получающих ингибитор комплемента

Country Status (6)

Country Link
EP (1) EP2825989A4 (de)
CN (1) CN104205155A (de)
EA (1) EA201400950A1 (de)
HK (1) HK1204693A1 (de)
IL (1) IL234680A0 (de)
WO (1) WO2013137912A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10272142B2 (en) 2013-11-13 2019-04-30 Shire Viropharma Incorporated Compositions and methods useful for the treatment of neuromyelitis optica spectrum disorders
CN105260974A (zh) * 2015-09-10 2016-01-20 济南市儿童医院 一种生成具有告签功能的电子病历方法及系统
CN115177291B (zh) * 2022-08-01 2023-11-10 首都医科大学附属北京朝阳医院 用于识别重症监护病房获得性肌无力的方法和装置

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6315720B1 (en) * 2000-10-23 2001-11-13 Celgene Corporation Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug
US20040117126A1 (en) * 2002-11-25 2004-06-17 Fetterman Jeffrey E. Method of assessing and managing risks associated with a pharmaceutical product
US20050169921A1 (en) * 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
US20060062734A1 (en) * 2004-09-20 2006-03-23 Melker Richard J Methods and systems for preventing diversion of prescription drugs
US20090220508A1 (en) * 2006-03-15 2009-09-03 Alexion Pharmaceuticals, Inc. Treatment Of Paroxysmal Nocturnal Hemoglobinuria Patients By An Inhibitor Of Complement
US8478605B2 (en) * 2006-07-17 2013-07-02 Walgreen Co. Appropriateness of a medication therapy regimen
WO2008021954A2 (en) * 2006-08-09 2008-02-21 Biogen Idec Ma Inc. Method for distribution of a drug
CA2742802C (en) * 2008-11-10 2019-11-26 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
WO2011091078A2 (en) * 2010-01-19 2011-07-28 Xencor, Inc. Antibody fc variants with enhanced complement activity

Also Published As

Publication number Publication date
IL234680A0 (en) 2014-11-30
WO2013137912A2 (en) 2013-09-19
EP2825989A2 (de) 2015-01-21
WO2013137912A3 (en) 2014-05-01
HK1204693A1 (en) 2015-11-27
EP2825989A4 (de) 2016-01-06
CN104205155A (zh) 2014-12-10

Similar Documents

Publication Publication Date Title
EA201401028A1 (ru) Фармацевтическая композиция, содержащая эмпаглифлозин и лекарственное средство от ожирения
IL227623B (en) Nanoparticle compositions comprising a population of particles, for use in the manufacture of a topical medicament for treating a subject suffering from or susceptible to a condition or disorder associated with sweat glands and/or sebaceous glands
MX2015006234A (es) Uso de akkermansia para tratar trastornos metabolicos.
UA117103C2 (uk) Сполука, яка має активність агоніста глюкагону
BR112015009948A8 (pt) Antagonistas de ativina-actrii, usos dos mesmos para tratamento de doenças ósseas e outros distúrbios e método para monitorar a eficácia do tratamento ou prevenção de uma doença óssea e outros distúrbios
EA201591166A1 (ru) Ингибиторы аутотаксина
BR112015018168A2 (pt) inibidores de rock suaves
EA201591679A1 (ru) Способ нетоксического лечения абстиненции, вызванной лекарственным средством
EA201590654A1 (ru) Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона
MX2015012559A (es) Novedosos fármacos de alta penetración y sus composiciones para el tratamiento de enfermedades de parkinson.
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
BR112012022552A8 (pt) uso de fenoterol e de análogos de fenoterol no tratamento de gliobastomas e astrocitomas e composição farmacêutica compreendendo os referidos compostos
PE20150161A1 (es) Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple
MX2017004772A (es) Composiciones y métodos para la administración fisiológica utilizando cannabidiol.
MX377688B (es) Métodos para administrar óxido nítrico a la sangre arterial o arterializada.
EA201590797A1 (ru) Препараты с модифицированным высвобождением опрозомиба
NZ700924A (en) Dosage regimen for a pi-3 kinase inhibitor
BR102012028120B8 (pt) Uso de um ou mais derivados de ingenol, composição farmacêutica e medicamento
EA201400950A1 (ru) Способы распространения комплемент-ингибирующих лекарственных средств среди пациентов, получающих ингибитор комплемента
JP2013520447A5 (de)
HK1225972A1 (zh) 利用拉喹莫德来延缓亨廷顿氏病的进展
EP3020395A4 (de) Verfahren zur herstellung einer mikrotropfenpille nach art der traditionellen chinesischen medizin sowie in diesem verfahren hergestellte mikrotropfenpille nach art der traditionellen chinesischen medizin
NZ706959A (en) Use of 3-n-butyl isoindoline ketone in preparation of drugs for preventing and treating cerebral infarction
EA201591603A1 (ru) Новые терапевтические комбинации миртазапина для применения при болевых расстройствах
EA201301275A1 (ru) Соединения, фармацевтические композиции и способ профилактики и лечения спаечного процесса